Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder

Circulation

Volumn 121, Issue 11, 2010, Pages 1329-1337

  Denchev, Peter ^a   Kaltman, Jonathan R ^b   Schoenbaum, Michael ^a   Vitiello, Benedetto ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Death, sudden; Drugs; Electrocardiography

Indexed keywords

CENTRAL STIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOLOGIST; CARDIOVASCULAR RISK; CHILD; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SCREENING TEST; SIDE EFFECT; SUDDEN DEATH;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; MALE; MARKOV CHAINS; MASS SCREENING; MEDICAL HISTORY TAKING; MODELS, STATISTICAL; PHYSICAL EXAMINATION; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; UNITED STATES;

EID: 77949808400     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.901256     Document Type: Article

References (39)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942-948.
2. Pliszka S, for the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921
3. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
4. Zuvekas SH, Vitiello B, Norquist NS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry. 2006;163:579-585.
5. Simpson GA, Cohen RA, Pastor PN, Reuben CA. Use of mental health services in the past 12 months by children aged 4-17 years: United States, 2005-2006. Hyattsville, Md: National Center for Health Statistics; 2008. NCHS data brief No. 8.
6. Vitiello B. Understanding the risk of using medications for attention-deficit/hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatric Clinic N Am. 2008;17: 459-474.
7. Berger S, Utech L, Fran Hazinski M. Sudden death in children and adolescents. Pediatr Clin North Am. 2004;51:1653-1677.
8. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006; 354:1445-1448.
9. GlaxoSmithKline. Dexedrine: prescribing information, 2006. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/ 017078s040lbl.pdf. Accessed July 14, 2009.
10. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166:992-1001.
11. American Academy of Pediatrics/American Heart Association. Clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr. 2008;29:335.
12. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407-2423.
13. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451-453.
14. Conway J, Wong KK, O'Connell C, Warren AE. Cardiovascular risk screening before starting stimulant medications and prescribing practices of Canadian physicians: impact of the Health Canada Advisory. Pediatrics. 2009;122:828-834.
15. Bader RS, Goldberg L, Sahn DJ. Risk of sudden cardiac death in young athletes: which screening strategies are appropriate? Ped Clin North Am. 2004;51:1421-1441.
16. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003;42:1959-1963.
17. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2007;115:1643-1655.
18. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
19. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000;3:200-211.
20. Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/ hyperactivity disorder in the United Kingdom. Value Health. 2008;11: 376-388.
21. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165.
22. Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR, for the Themta Cooperative Group. MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48:484-500.
23. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliot GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40:188-196
24. Medicare Physician Fee Schedule, 2009. Available at: http://www.cms.hhs. gov/PFSLookup/. Accessed March 2009.
25. Thomson Healthcare. Red Book 2008. New York, NY: Thomson Reuters; 2008.
26. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
27. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007; 56:1-39.
28. Berger S, Whitstone BN, Frisbee SJ, Miner JT, Dhala A, Pirrallo RG, Utech LM, Sachdeva RC. Cost-effectiveness of Project ADAM: a project to prevent sudden cardiac death in high school students. Pediatr Cardiol. 2004;25:660-667.
29. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. JAMA. 1996;276:199-204
30. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press 1996.
31. Fuller CM, McNulty CM, Spring DA, Arger KM, Bruce SS, Chryssos BE, Drummer EM, Kelley FP, Newmark MJ, Whipple GH. Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc. 1997;29:1131-1138.
32. Fuller CM. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc. 2000;32: 887-890.
33. Drezner JA. Contemporary approaches to the identification of athletes at risk for sudden cardiac death. Curr Opin Cardiol. 2008;23:494-501.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
35. Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat. 2008;10:1-14.
36. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel of cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
37. Leslie LK, Alexander ME, Trikalinos TA, Cohen JT, Parsons SK, New-burger JW. Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. Circ Cardiovasc Qual Outcomes. 2008;1: 134-137.
38. Douglas PS. Saving athletes' lives: a reason to find common ground? J Am Coll Cardiol. 2008;52:1997-1999.
39. Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliot G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005;162:1628-1636